What Innovative Industrial Properties’ (IIPR) New Dividends Could Mean for this Stock

Today Innovative Industrial Properties, Inc. (IIPR) declared a Q4 2019 dividend of $1.00 per share of common stock, equating to an approximate 28% increase above the company's Q3 2019 dividend of $0.78 per share, and about a 186% increase above its Q4 2018 dividend of $0.35 per share. IIPR is the first and only REIT on the New York Stock Exchange to specialize in the legal U.S. cannabis industry. This dividend is the sixth dividend increase since the company's IPO back in December 2016, and breaks down to an annualized dividend of $4.00 per common share.  As for the company's 9.00% Series A Cumulative Redeemable Preferred Stock, IIPR has also declared a regular quarterly dividend of $0.5625 per share, which will be payable on January 15, 2020 to stockholders of record at the close of business on December 31, 2019.  Innovative Industrial Properties, Inc. seems to be outperforming its peers in the Finance sector this year. Looking at the most recent data, the company has returned 70.54% so far, versus the Finance sector's average of 18.13% on a year-to-date basis.  It also appears that IIPR is outperforming its peers in the REIT and Equity Trust category, which comparatively has only gained an average of 25.71% so far this year. Innovative Industrial Properties, Inc. has a market capitalization of $926m. The company has increased its earnings per share (EPS) by an average of 174% per year, throughout the last three years (using a line of best fit). It also grew revenue 159% during the last year. Throughout the past 3 years, IIPR has delivered a total shareholder return of 369%. IIPR is a self-advised Maryland corporation focused on the acquisition, ownership and management of regulated medical-use marijuana facilities. The company partners with industrial properties that are leased to qualified, state-licensed operators. The company partners with cannabis operators by supplying them with capital via the acquisition and lease-back of their real estate assets, as well as offering other creative real estate-based capital solutions. Innovative Industrial Properties, Inc. owns 29 properties across Arizona, California, Colorado, Illinois, Maryland, Massachusetts, Michigan, Minnesota, New York, Nevada, Ohio and Pennsylvania.  These properties total roughly 2.1 million rentable square feet, which are 100% leased with a weighted-average remaining lease term of about 15.8 years. IIPR is also one of few cannabis stocks that issues dividend payments to its shareholders. As a REIT, the company is required to distribute 90% of taxable income to shareholders in the form of dividend payments. According to the company website, "Our national portfolio is comprised of specialized industrial and greenhouse buildings, 100% leased to state-licensed medical-use cannabis growers. These facilities are mission-critical for our operators and well located in states with robust medical-use regulatory environments."  
Innovative Industrial Properties Inc. (IIPR) rose $0.20 (+0.27%) in after-hours trading Tuesday. Year-to-date, IIPR has gained 131.56%, versus a 17.96% rise in the benchmark S&P 500 index during the same period.

About the Author: Eric Bowler

eric-bowlerEric Bowler is an accomplished journalist providing in-depth insights for more than two decades. Over the past several years his focus has been on the marijuana industry, with a special interest in cannabis growth stocks. His daily coverage of the industry keeps him on top of the key trends with the goal of helping investors make well-informed decisions.
NYSE:MJ December 10, 2019 4:55pm

What Caused Today’s Rally in Cannabis Stocks?

NYSE:MJ December 9, 2019 5:41pm

What Aphria’s (APHA) $80 million Financing Could Mean for This Stock

NYSE:MJ December 5, 2019 11:20am

What Does Aurora Cannabis’ CBD Approval Mean for the Stock?                   

NYSE:MJ December 3, 2019 4:52pm

How Important is Canopy Growth’s (CGC) Newly Obtained Beverage License?  

ETF BASIC NEWS November 27, 2019 11:22am

Why Did the Cannabis ETF MJ Rally 10% Yesterday?

NYSE:MJ November 22, 2019 12:50pm

Are Shares of Aphria (APHA) Poised to Surge?

ETF BASIC NEWS November 20, 2019 12:05pm

Organigram (OGI) Stock Down on Lowered Guidance, is it a Buying Opportunity?  

ETF BASIC NEWS November 14, 2019 12:15pm

How is Aurora Cannabis (ACB) Planning to Dominate North America?

ETF BASIC NEWS November 8, 2019 10:55am

Is GW Pharmaceuticals (GWPH) a Buy Before it Reports Earnings?

Earlier this week, an H.C. Wainwright analyst initiated coverage of GW Pharmaceuticals (GWPH), adding to the buzz already surrounding this increasingly popular cannabis stock. On Wednesday, H.C. Wainwright analyst Douglas Tsao initiated coverage, giving the stock a "Buy" rating and $170 price target. In a note to investors, Tsao said that he expects GWPH stock to move higher as its quarterly results demonstrate that Epidiolex's launch is sustainable. Additionally, he believes that dose titration and penetration into off-label patient populations "should fuel growth and offer a bridge" to the anticipated label expansion into the tuberous sclerosis complex by mid-2020. In GW Pharmaceuticals' most recent earnings release, the company surprised investors by posting a positive earnings of 64.9%. GWPH has exceeded industry expectations in each of the most recent four quarters, with an average positive earnings of 26.7%. GWPH stock has increased 20.94% in the past month, which has outpaced both the Medical sector's gain of 3.22% and the S&P 500's gain of 2.66%, during the same period. How GWPH got to where it is now GW Pharmaceuticals first commercially launched Epidolex in the United States last November. Epidolex is the first cannabis-derived drug for patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome. And while GWPH was not immune to the boom and bust cycle that ravaged cannabis stocks between the spring and fall of this year, GW Pharmaceuticals seems to be rebounding nicely compared to its industry peers. Throughout the past few months, the company has experienced an increase in receptiveness and demand for Epidolex in the United States, as more and more physicians are recommending the drug in their prescriptions.  Investors anticipate a growing level of market penetration from the third quarter as well. They attribute this to market research conducted on Epidiolex during the second quarter, which seemed to drive awareness for LGS and Dravet, meaning that Epidiolex's third quarter sales are likely to have gained courtesy of more prescriptions.  GW Pharmaceuticals' focus has been on making Epidiolex a leading brand for epilepsy treatment. Adding to the company's success in this regard, the European Commission recently approved the marketing authorization of Epidiolex for patients aged 2 years and older. This too, is anticipated to help the company's third quarter results. As far as coverage determination is concerned, GWPH has been increasing payor access for some time now. Investors anticipate that this will also continue in the third quarter. Many investors anticipate that GW Pharmaceuticals' Q3 earnings should reflect the expansion of the Epidiolex label to TSC on a favorable outcome of Phase 3 trial data for Epidiolex, and the treatment of seizures associated with tuberous sclerosis complex. Another one of GWPH's cannabis-derived drugs that's been rising in popularity is Sativex, which is used to treat muscle spasms. Expect a reflection on this drug's performance in the upcoming earnings report. GW Pharmaceuticals also has a CBDV program that's been performing well. One can expect more news on this in the upcoming report. Keep an eye out for the Q3 earnings release due next week on November 5, 2019.
GW Pharmaceuticals PLC ADR (GWPH) was unchanged in after-hours trading Friday. Year-to-date, GWPH has declined N/A%, versus a 15.18% rise in the benchmark S&P 500 index during the same period.

About the Author: Eric Bowler

eric-bowlerEric Bowler is an accomplished journalist providing in-depth insights for more than two decades. Over the past several years his focus has been on the marijuana industry, with a special interest in cannabis growth stocks. His daily coverage of the industry keeps him on top of the key trends with the goal of helping investors make well-informed decisions.
NYSE:MJ November 1, 2019 5:49pm

Will Innovative Industrial Properties’ (IIPR) New Partnerships & Acquisitions Send Its Stock Soaring?

NYSE:MJ October 31, 2019 5:02pm

Get Free Updates

Join over 50,000 investors who get the latest news from ETFDailyNews.com!

Most Popular


From Our Partners


Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories